US Inhalation Systems Market Forecast up to 2024

Description

US Inhalation Systems Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Access the PDF sample of the report @ https://www.orbisresearch.com/contacts/request-sample/2512151

Overview:
The emergence of inhaled drug therapy has been a boon for patients with respiratory conditions such as COPD and asthma because of its painless and flexible administration when compared to injections. There are various kinds of inhalation systems available in the market, and these include inhalers and nebulizers. The two most commonly widespread respiratory diseases are asthma and COPD. According to WHO, around 235 million people are currently suffering from asthma, and it is very common in children. Chronic respiratory diseases such as asthma and COPD are responsible for substantial financial and health burden in the US, and in 2015, 6.7% deaths in the US were due to chronic respiratory diseases. Chronic obstructive pulmonary disease is the third leading cause of death across the globe, accounting for approximately 3 million deaths in 2016. State of West Virginia has the highest prevalence of COPD, and around 12% of the population are diagnosed with COPD.

The US inhalation systems market is driven by an upsurge in the prevalence of respiratory diseases, increasing geriatric population, and favorable reimbursement. However, side effects allied with the drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may slow down the growth of the market in the US.

Market Analysis: The “US Inhalation Systems Market” is estimated to witness a CAGR of 5.8% during the forecast period 2018–2024. The US market is analyzed based on three segments – products, applications, and end-users.
Product Analysis: The US inhalation systems market, by product, is segmented into inhalers and nebulizers. The market by inhalers type is further segmented into dry powder inhalers and metered dose inhalers. The market by nebulizers is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh nebulizer. Inhalers occupied a major market share in 2017 and nebulizers segment is anticipated to grow at a high CAGR during the forecast period. The extensive usage of inhalers in the treatment of various respiratory illness such as asthma, chronic obstructive pulmonary disorder, and others makes the segment the major shareholder.

Application Analysis: The US inhalation systems market, by application, is segmented into asthma, chronic obstructive pulmonary disease (COPD), and others. Asthma occupied a major market share in 2017 and COPD is expected to grow at the highest rate in the next five years.

End-users Analysis: The US inhalation systems market by end-users is segmented into hospitals, ambulatory care centers, and home care centers. Hospitals occupied a major market share in 2017, and home care segment is expected to grow during the forecast period due to ease in the usage of modern products, less homecare cost, and the obtainability of reimbursement.

Key Players:
Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson and Company are few of the key players in the US inhalation systems market.

Competitive Analysis:
There is an increase in approvals in recent years due to the popularity of the systems and also drug companies are launching new inhalation systems and collaborating with other vendors to develop innovative devices in the market. For instance, in February 2017, FDA approved two products developed by Teva Pharmaceutical Industries Ltd., ArmonAir RespiClick and AirDuo RespiClick, to treat adolescent and adult patients with asthma. In October 2017, FDA approved new inhalation device, named TD-300/A developed by United Therapeutics Corporation, for use with Tyvaso Inhalation Solution. The first triple combination inhaler named Trimbow launched for COPD in August 2017 and in February 2018, Teva Pharmaceutical Industries Ltd. announced the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in the US.

Benefits: The report provides complete details about the products offered by inhalation system companies in various therapeutic verticals. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Companies Mentioned:
Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson

Browse the full report @ https://www.orbisresearch.com/reports/index/us-inhalation-systems-market-forecast-up-to-2024

Table of Contents

1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Advantages of inhalation systems 14
3.3 Limitations associated with inhalation systems 14
3.4 Segmented Addressable Market (SAM) 14
3.5 Trends of the US inhalation systems market 15
3.6 Related Markets 16
3.6.1 Sleep Apnea 16
3.6.2 Anesthesia 16
3.6.3 Pulmonary Medicine 17
4 Market Outlook 18
4.1 History of Inhalation systems 18
4.2 Market segmentation 18
4.3 PEST Analysis 19
4.4 Porter 5(Five) Forces 20
5 Market Characteristics 22
5.1 DRO – US Inhalation Systems Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Rising prevalence’s of respiratory diseases 22
5.1.1.2 Favorable reimbursement 23
5.1.1.3 Increasing geriatric population 23
5.1.2 Opportunities 23
5.1.2.1 Advancement in technology 23
5.1.2.2 Upsurge in the demand for home-care therapeutic devices 24
5.1.3 Restraints 24
5.1.3.1 Side effects allied with drug inhalation 24
5.1.3.2 Unattainability of solo effective inhaler device that can treat many disease conditions 24
5.2 DRO – Impact Analysis 25
5.3 Key Stakeholders 26
6 By Products: Market Size and Analysis 27
6.1 Overview 27
6.2 Inhalers 29
6.2.1 Dry powder inhalers 31
6.2.2 Metered dose inhaler 32
6.2.3 Soft mist inhaler 34
6.3 Nebulizers 34
6.3.1 Ultrasonic Nebulizers 36
6.3.2 Pneumatic/jet Nebulizers 37
6.3.3 Mesh Nebulizers 38
7 By Applications: Market Size and Analysis 40
7.1 Overview 40
7.2 Asthma 40
7.3 Chronic obstructive pulmonary disease (COPD) 41
7.4 Others 41
8 By End-Users: Market Size and Analysis 43
8.1 Overview 43
8.2 Hospitals 43
8.3 Ambulatory care centers 44
8.4 Home Care 44
9 Regions: Market Size and Analysis 45
9.1 Overview 45
9.2 United States 45
10 Competitive Landscape 48
10.1 Overview 48
11 Vendor Profiles 50
11.1 Boehringer Ingelheim GmbH 50
11.1.1 Overview 50
11.1.2 Business Units 52
11.1.3 Geographic Presence 53
11.1.4 Business focus 54
11.1.5 SWOT analysis 54
11.1.6 Business Strategy 55
11.2 Omron Corp. 56
11.2.1 Overview 56
11.2.2 Business Units 58
11.2.3 Geographic Presence 60
11.2.4 Business Focus 60
11.2.5 SWOT Analysis 61
11.2.6 Business Strategies 61
11.3 PARI GmbH 62
11.3.1 Overview 62
11.3.2 Business Focus 63
11.3.3 SWOT Analysis 63
11.3.4 Business Strategies 63
11.4 Philips Healthcare 64
11.4.1 Overview 64
11.4.2 Business Units 73
11.4.3 Geographic Presence 73
11.4.4 Business Focus 74
11.4.5 SWOT Analysis 75
11.4.6 Business Strategy 75
11.5 3M 76
11.5.1 Overview 76
11.5.2 Business Units 78
11.5.3 Geographic Presence 79
11.5.4 Business Focus 79
11.5.5 SWOT Analysis 79
11.5.6 Business Strategy 80
12 Companies to Watch For 81
12.1 AptarGroup, Inc. 81
12.1.1 Overview 81
12.2 Teleflex Incorporated 82
12.2.1 Overview 82
12.3 Agilent Technologies 83
12.3.1 Overview 83
12.3.2 Agilent Technologies, Inc.: Recent Developments 84
12.4 Inspiro Medical Ltd. (a subsidiary of Opko Health, Inc.) 87
12.4.1 Overview 87
12.4.2 Inspiro Medical Ltd: Recent Developments 87
12.5 Monaghan Medical Corporation 87
12.5.1 Overview 87
12.5.2 Monaghan Medical Corporation: Recent Developments 88
12.6 Astra Zeneca PLC 89
12.6.1 Overview 89
12.6.2 AstraZeneca PLC: Recent Developments 89
12.7 GlaxoSmithKline plc 90
12.7.1 Overview 90
12.7.2 Glaxosmithkline Plc: Recent Developments 91
12.8 TEVA Pharmaceuticals Industries Ltd 93
12.8.1 Overview 93
12.8.2 TEVA Pharmaceuticals Industries LTD.: Recent Developments 93
12.9 Beckton Dickinson and Company 94
12.9.1 Overview 94
12.9.2 Beckton Dickinson and Company: Recent Developments 95
13 Annexure 97
13.1 Abbreviations 97

Direct purchase the report @ https://www.orbisresearch.com/contact/purchase-single-user/2512151

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (972)-362-8199; +91 895 659 5155

Links:
https://www.orbisresearch.com/contacts/enquiry-before-buying/2512151
https://www.orbisresearch.com/contacts/discount/2512151